About Pharmacosmos
Pharmacosmos is a Healthcare company. Pharmaceutical development focused on carbohydrate chemistry for iron deficiency and anaemia treatments. Pharmacosmos has completed 1 acquisition, including G1 Therapeutics. Pharmacosmos offers products and services including Iron Deficiency Treatments and Petadeferitrin. Its focus areas include Pharmaceuticals, Biotechnology, Drug Development and Iron Deficiency Treatments. Its legal entity is Pharmacosmos A/S.
Company details
Pharmacosmos is recognized as a family-held company that specializes in carbohydrate chemistry for developing treatments aimed at iron deficiency and anaemia, affecting over a billion people globally. Expertise in iron metabolism is utilized to conduct clinical trials and research programs, including products like Petadeferitrin for iron overload. A global presence is maintained in more than 40 countries through collaborations and partnerships, while an inclusive culture supports career opportunities and sustainability efforts. Animal health solutions are also addressed, ensuring innovative approaches to health challenges are pursued without promotional emphasis.
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Social LinkedIn
- Legal Name Pharmacosmos A/S
- Investments & Acquisitions
Products & Services of Pharmacosmos
Pharmacosmos offers a comprehensive portfolio of products and services, including Iron Deficiency Treatments and Petadeferitrin.
Treatments for iron deficiency and anaemia are developed using carbohydrate chemistry expertise.
An iron chelator for conditions like iron overload is developed based on expertise in iron metabolism.
People of Pharmacosmos
90 people are tracked at Pharmacosmos (46 in leadership, 4 in board & advisors, 40 in team).
| Name | Role | Group |
|---|---|---|
Christian von der Recke-Heisel - Issues With the Iron Dextran Registration… | International Sales And Marketing Director, Veterinary | Leadership |
Thomas Delvin | Head Of Clinical Science | Leadership |
Tobias S. Christensen | President & CEO | Leadership |
Robert Guglielmetti | CFO & EVP | Leadership |
Claes C. Strøm | CCO & VP | Leadership |
Ingeborg Lohmann Laursen | VP, Quality & Regulatory Affairs | Leadership |
Lars W. Søgaard | VP, Supply Chain & Administration | Leadership |
Lars L. Thomsen | CMO & VP | Leadership |
Josh Franklin | President, Pharmacosmos Therapeutics Inc., US | Leadership |
Milena Jordanova Olsen | VP & General Counsel | Leadership |
Lise Larsen | VP, Production | Leadership |
Trine Kolding | Head Of Clinical Operations | Leadership |
Dirk Eyding | Clinical Science Director | Leadership |
Henrik Parker | Chief Financial Officer & EVP | Leadership |
Jeppe Sørensen | International Market Access Director | Leadership |
Ditte Lindboe | Executive Vice President, HR (chro) | Leadership |
Christian Amberg | Director Business Development And Strategy | Leadership |
Marie Maguire | Celtic Business Director | Leadership |
Robert Mueller | Head Of Marketing | Leadership |
Sharon Connors-Jones | Senior Director Of Human Resources, Uk/ire & Northern Europe | Leadership |
70 more people are available in the full profile.
Complete people profiles for Pharmacosmos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pharmacosmos
Pharmacosmos has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include G1 Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Cancer therapeutics are developed via a proprietary kinase platform. | g1therapeutics.com | Chapel Hill, United States | 2008 | Aug 2024 | $405M |
Complete acquisition details for Pharmacosmos
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of Pharmacosmos
Websites that share an audience with Pharmacosmos (pharmacosmos.com).
Websites whose visitors overlap most with Pharmacosmos. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| francoindian.com | 78% | 2.9K | #1,977,293 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pharmacosmos
Pharmacosmos is recognized as a family-held company that specializes in carbohydrate chemistry for developing treatments aimed at iron deficiency and anaemia, affecting over a billion people globally. Expertise in iron metabolism is utilized to conduct clinical trials and research programs, including products like Petadeferitrin for iron overload. A global presence is maintained in more than 40 countries through collaborations and partnerships, while an inclusive culture supports career opportunities and sustainability efforts. Animal health solutions are also addressed, ensuring innovative approaches to health challenges are pursued without promotional emphasis.
Pharmacosmos offers Iron Deficiency Treatments and Petadeferitrin.
Pharmacosmos has made 1 acquisition, including G1 Therapeutics.
Pharmacosmos operates through Pharmacosmos A/S.